Xie, R.

irinotecan patient cancer pharmacokinetic -38 variant ugt 1a group sn -38 study table analysis polymorphism sn -38g parameter allele infusion ratio treatment value variant type patient metabolite extent irinotecan disposition variability glucuronidation plasma variation 600 mg auc ratio metabolism 2002. genotype research cancer patients transporter blood effect dosing result sparreboom pharmacogenetic lactone 90- min i.v mathijssen interindividual variability disposition pharmacokinetic parameters verweij enzyme protein sample population irinotecan pharmacokinetics frequency association 350 mg /m concentration sn -38 glucuronidation ugt 1a polymorphism oncol irinotecan pharmacokinetic parameters difference p-glycoprotein expression fixed-dose group abc transporters wild-type linkage pharmacokinetic data activity irinotecan metabolism pyrosequencing hepatic 0.00 toxicity range version 1.00 resistance